Despite an improved understanding of its pathophysiology and a wide range of new treatments, cardiovascular disease (CVD) remains a serious public health issue and the number one cause of mortality in the United States. Conditions that promote chronic systemic inflammation, such as obesity, cancer, and autoimmune and infectious diseases, are now known to play an important role in promoting CVD by inducing the expression of endothelial adhesion molecules and chemokines; these in turn promote leukocyte adherence and infiltration, which initiates and spurs the progression of CVD. In response to this new understanding, researchers are evaluating the potential cardiovascular benefits of new-generation therapies based on endogenous molecules with anti-inflammatory properties. Similarly, targeted approaches that leverage the phenotypic differences between non-inflamed and inflamed endothelia have the potential to selectively deliver therapeutics and decrease the morbidity and mortality of CVD patients. In this review, we discuss the role of inflammation in CVD and explore the therapeutic potential of targeting inflamed vasculature through conventional and biomimetic approaches.

Molinaro, R., Boada, C., Del Rosal, G., Hartman, K., Corbo, C., Andrews, E., et al. (2016). Vascular Inflammation: A Novel Access Route for Nanomedicine. METHODIST DEBAKEY CARDIOVASCULAR JOURNAL, 12(3), 169-174 [10.14797/mdcj-12-3-169].

Vascular Inflammation: A Novel Access Route for Nanomedicine

Corbo C;
2016

Abstract

Despite an improved understanding of its pathophysiology and a wide range of new treatments, cardiovascular disease (CVD) remains a serious public health issue and the number one cause of mortality in the United States. Conditions that promote chronic systemic inflammation, such as obesity, cancer, and autoimmune and infectious diseases, are now known to play an important role in promoting CVD by inducing the expression of endothelial adhesion molecules and chemokines; these in turn promote leukocyte adherence and infiltration, which initiates and spurs the progression of CVD. In response to this new understanding, researchers are evaluating the potential cardiovascular benefits of new-generation therapies based on endogenous molecules with anti-inflammatory properties. Similarly, targeted approaches that leverage the phenotypic differences between non-inflamed and inflamed endothelia have the potential to selectively deliver therapeutics and decrease the morbidity and mortality of CVD patients. In this review, we discuss the role of inflammation in CVD and explore the therapeutic potential of targeting inflamed vasculature through conventional and biomimetic approaches.
Articolo in rivista - Articolo scientifico
C-reactive protein; cardiovascular diseases; drug delivery platform; endotheliopathies; endothelium; NF-kB; statins; theranostic; vascular inflammation;
C-reactive protein; NF-kB; cardiovascular diseases; drug delivery platform; endotheliopathies; endothelium; statins; theranostic; vascular inflammation
English
2016
12
3
169
174
reserved
Molinaro, R., Boada, C., Del Rosal, G., Hartman, K., Corbo, C., Andrews, E., et al. (2016). Vascular Inflammation: A Novel Access Route for Nanomedicine. METHODIST DEBAKEY CARDIOVASCULAR JOURNAL, 12(3), 169-174 [10.14797/mdcj-12-3-169].
File in questo prodotto:
File Dimensione Formato  
Vascular inflammation_Molinaro.pdf

Solo gestori archivio

Dimensione 205.89 kB
Formato Adobe PDF
205.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/217930
Citazioni
  • Scopus 24
  • ???jsp.display-item.citation.isi??? ND
Social impact